| Literature DB >> 23341693 |
Claudia Luévano-Contreras1, Ma Eugenia Garay-Sevilla, Kazimierz Wrobel, Juan M Malacara, Katarzyna Wrobel.
Abstract
The augmented consumption of dietary advanced glycation end products (dAGEs) has been associated with increased oxidative stress and inflammation, however, there is insufficient information over the effect on insulin resistance. The objective of the present study is to investigate the effect of dAGEs restriction on tumor necrosis factor-α (TNF-α), malondialdehyde, C-reactive protein (CRP), and insulin resistance in DM2 patients. We carried out a randomized 6 weeks prospective study in two groups of patients: subjects with a standard diet (n = 13), vs low dAGEs (n = 13). At the beginning and the end of study, we collected anthropometric measurements, and values of circulating glucose, HbA1c, lipids, insulin, serum AGEs, CRP, TNF-α and malondialdehyde. Anthropometric measurements, glucose, and lipids were similar in both groups at base line and at the end of the study. Estimation of basal dAGEs was similar in both groups; after 6 weeks it was unchanged in the standard group but in the low dAGEs group decreased by 44% (p<0.0002). Changes in TNF-α levels were different under standard diet (12.5 ± 14.7) as compared with low dAGEs (-18.36 ± 17.1, p<0.00001); changes in malondialdehyde were different in the respective groups (2.0 ± 2.61 and -0.83 ± 2.0, p<0.005) no changes were found for insulin levels or HOMA-IR. In conclusion, The dAGEs restriction decreased significantly TNF-α and malondialdehyde levels.Entities:
Keywords: TNF-α; advanced glycation end products; diabetes mellitus; diet; malondialdehyde
Year: 2012 PMID: 23341693 PMCID: PMC3541414 DOI: 10.3164/jcbn.12-40
Source DB: PubMed Journal: J Clin Biochem Nutr ISSN: 0912-0009 Impact factor: 3.114
General characteristics of both groups at baseline
| S-dAGEs | L-dAGEs | t/ | ||
|---|---|---|---|---|
| mean ± SD | mean ± SD | |||
| Gender (M/F) | 2/11 | 1/12 | ||
| Age (years) | 48.5 ± 6.2 | 46.0 ± 5.0 | 1.14 | 0.26 |
| Year since diagnosis of DM | 6.3 ± 4.9 | 4.1 ± 3.5 | 1.31 | 0.2 |
| Weight (kg) | 69.7 ± 14 | 72 ± 10.4 | 1.82 | 0.31 |
| BMI | 28.8 ± 4.76 | 29.8 ± 4.0 | 1.34 | 0.62 |
| SBP (mmHg) | 130 ± 19 | 121 ± 21 | 1.26 | 0.69 |
| DBP (mmHg) | 82 ± 11 | 75 ± 11 | 1.01 | 0.99 |
| Glucose (mg/dl) | 151.3 ± 55.8 | 147.7 ± 64.9 | 1.36 | 0.6 |
| HbA1c (%) | 9.08 ± 2.28 | 8.05 ± 1.46 | 1.5 | 0.14 |
| Total-cholesterol (mg/dl) | 185.6 ± 35.2 | 162.4 ± 35.2 | 1.03 | 0.96 |
| Triglycerides (mg/dl) | 239.1 ± 97.4 | 203.7 ± 106.3 | 1.11 | 0.86 |
| LDL-C (mg/dl) | 104.4 ± 34.4 | 88.9 ± 31.3 | 1.24 | 0.71 |
| HDL-C (mg/dl) | 44.1 ± 11.6 | 42.5 ± 8.9 | 1.61 | 0.42 |
| Fluorescent serum AGEs (arbitrary units) | 6.91 ± 1.44 | 7.1 ± 2 | 1.9 | 0.29 |
| Malondialdehyde (µmol/l) | 3.5 ± 1.1 | 4.3 ± 2 | 3.42 | <0.04 |
| PCR (mg/l) | 10.2 ± 6.2 | 6.9 ± 6.1 | 1.01 | 0.98 |
| TNF-α (pg/ml) | 14.4 ± 8.10 | 34.9 ± 18.7 | 2.95* | <0.002 |
| Insulin (µU/ml) | 18.6 ± 17.2 | 14.4 ± 6.8 | 6.33 | <0.003 |
| Homa-IR | 6.9 ± 6.6 | 5.3 ± 3.2 | 4.15 | <0.02 |
| Kilocal/day | 1737 ± 393 | 1619 ± 324 | 1.47 | 0.51 |
| Carbohydrates (g/day) | 243.4 ± 75.7 | 240 ± 67.5 | 1.26 | 0.7 |
| Fats (gr/day) | 50.7 ± 14.7 | 40.5 ± 13.4 | 1.21 | 0.74 |
| Proteins (gr/day) | 73.1 ± 11.4 | 70.4 ± 20.7 | 3.37 | <0.04 |
| dAGEs (as CML, KU/day) | 9910 ± 4164 | 8956 ± 3587 | 1.35 | 0.61 |
We included 34 patients, 17 in the group with the S-dAGEs and 17 the group with L-dAGEs; 5 of them were excluded because during the follow-up they showed clinical evidence of an infectious disease, and 3 because they required modification in the hypoglycemic treatment. * Mann-Whitney U test.
Changes in metabolic variables after six weeks, as compared with basal levels in the group of study
| S-dAGEs | L-dAGEs | T/ | ||
|---|---|---|---|---|
| Glucose (mg/dl) | 4.55 ± 35.6 | –18 ± 56.7 | –1.21 | 0.24 |
| Total-cholesterol (mg/dl) | –9.0 ± 44.9 | 5.7 ± 43.3 | 0.84 | 0.41 |
| Triglycerides (mg/dl) | –3.7 ± 80.2 | 5.4 ± 59.0 | 0.33 | 0.74 |
| HDL-cholesterol (mg/dl) | –4.2 ± 10.3 | –2.5 ± 7.4 | 0.48 | 0.64 |
| HbA1c (%) | –0.11 ± 1.9 | 0.19 ± 1.3 | 0.46 | 0.65 |
| Fluorescent serum AGEs (arbitrary units) | 0.68 ± 2.1 | 0.29 ± 1.3 | –0.57 | 0.57 |
| Malondialdehyde (µmol/l) | 2.0 ± 2.61 | –0.83 ± 2.0 | –3.12 | <0.005 |
| PCR (mg/l) | –1.21 ± 5.5 | –1.69 ± 5.4 | 0.23 | 0.82 |
| TNF-α (pg/ml) | 12.5 ± 14.7 | –18.36 ± 17.1 | –4.92 | <0.00001 |
| Insulin (µU/ml) | –7.0 ± 17.0 | –4.81 ± 7.3 | –0.67 | 0.5 |
| HOMA-IR | –2.5 ± 6.1 | –2.29 ± 3.7 | 0.13 | 0.89 |
| Kilocal/day | –222 ± 415.1 | –110 ± 307 | 0.78 | 0.44 |
| Carbohydrates (g/day) | –32.0 ± 73.2 | –23.6 ± 61.9 | 0.3 | 0.76 |
| Fats (g/day) | –6.1 ± 16.2 | 0.13 ± 20.6 | 0.85 | 0.4 |
| Proteins (g/day) | –9.6 ± 14.6 | –3.63 ± 22.0 | 0.82 | 0.42 |
| dAGEs (as CML, KU/day) | 2304 ± 4169 | –4990 ± 3380 | –4.9 | <0.00005 |
*Mann-Whitney U test.
Fig. 1Changes in TNF-α and MDA in type 2 diabetic patients. Changes in TNF-α and MDA in type-2 diabetic patients after 6 weeks with low AGEs diet as compared with those under Standard AGEs diet.